The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Grant | Alive

Total Raised




Last Raised

$1.05M | 5 yrs ago



About Genzyme

Genzyme, a biotechnology company, engages in the discovery and development of products and services primarily in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases, and endocrinology.

Genzyme Headquarters Location

50 Binney St

Cambridge, Massachusetts, 02142,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Genzyme

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Genzyme is included in 2 Expert Collections, including Medical Devices.


Medical Devices

295 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA


Biopharma Tech

838 items

Genzyme Patents

Genzyme has filed 544 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Amines, Piperidines, Piperazines, Pyridines, Fluoroarenes


Application Date


Grant Date



Related Topics

Amines, Piperidines, Piperazines, Pyridines, Fluoroarenes



Latest Genzyme News

DMTs may reduce risk for becoming wheelchair dependent in patients with PPMS

Jul 28, 2022

Disclosures: Portaccio reported receiving travel grants for participation in advisory board and/or speaking activities from Biogen, Merck, Sanofi Genzyme, Novartis, Roche, Celgene and Teva and serving on the editorial board of Frontiers in Neurology and Brain Sciences. Please see the study for all other authors’ relevant disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio In patients with primary progressive MS who experience persistent inflammatory activity, disease-modifying therapies were linked to a reduced risk for becoming wheelchair dependent, according to a study in JAMA Neurology. “Although several disease-modifying treatments are available for the treatment of relapsing-remitting MS, in the PPMS phenotype, with the exception of ocrelizumab, previous randomized clinical trials of current licensed [disease-modifying therapies] were found to be ineffective,” Emilio Portaccio, MD, of the department of neuroscience, psychology, pharmacology and children’s health at the University of Florence in Italy, and colleagues wrote. Source: Adobe Stock. Portaccio and fellow researchers sought to investigate the effectiveness of disease-modifying therapies (DMTs) on the risk for becoming wheelchair dependent in a real-world population of patients with PPMS by conducting a multicenter, observational, retrospective, comparative effectiveness study. They obtained data from the Italian MS register in November 2018 and analyzed it from June to December 2021. From an initial cohort of 3,298 patients with PPMS, 665 participants (mean age, 43.0 years; 55% women) were included and had at least 3 years of Expanded Disability Status Scale (EDSS) evaluations and 3 years of follow-up. Of those, 409 were selected for propensity score matching (288 treated, 121 untreated). Researchers assessed the risk for becoming wheelchair bound (an EDSS score of 7) through multivariable Cox regression models and considered participants who received DMT before reaching a score of 7 treated. DMT was assessed as a time-dependent variable and by class of DMT (moderately and highly effective). During the study follow-up, 37% of patients in the matched cohort (152 of 409) reached an EDSS score of 7 after a mean follow-up of 10.6 years. A higher EDSS score at baseline (adjusted hazard ratio = 1.32; 95% CI, 1.13-1.55), superimposed relapses (aHR = 2.37; 95% CI, 1.24-4.54) and DMT exposure (aHR = 1.75; 95% CI, 1.04-2.94) were associated with a higher risk for an EDSS score of 7. Conversely, the interaction interval between DMT and superimposed relapses correlated with a reduced risk for becoming wheelchair bound (aHR = 0.33; 95% CI, 0.16-0.71). When researchers considered treatment according to DMT class and included DMT as a time-dependent covariate, they reached similar conclusions. “Results of this comparative effectiveness research study suggest that inflammatory activity is a modifiable risk factor of long-term disability in PPMS,” Portaccio and colleagues wrote. “In these patients, DMT exposure may be associated with a decreased risk of becoming wheelchair bound.” Read more about

  • When was Genzyme founded?

    Genzyme was founded in 1981.

  • Where is Genzyme's headquarters?

    Genzyme's headquarters is located at 50 Binney St, Cambridge.

  • What is Genzyme's latest funding round?

    Genzyme's latest funding round is Grant.

  • How much did Genzyme raise?

    Genzyme raised a total of $1.05M.

  • Who are the investors of Genzyme?

    Investors of Genzyme include Cystic Fibrosis Foundation, Sanofi, SV Health Investors and Oak Investment Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.